Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

EARNINGS: Alliance Pharma swings to profit; DG Innovate loss widens

30th Sep 2024 18:37

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Alliance Pharma PLC - Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines - Swings to pretax profit of GBP12.7 million for the six months to June 30, from a loss of GBP6.8 million a year prior. Revenue grows 3.1% to GBP83.9 million from GBP81.4 million. Group revenue is expected to build throughout the second half of 2024 as new product launches gain momentum, and the company says this revenue will support further investment in marketing and innovation. Chief Executive Officer Nick Sedgwick says: "I am pleased by the performance we delivered in the first half of 2024 as we continue to see the benefits of our investment in both marketing and innovation. Our free cash flow is expected to build strongly throughout the remainder of 2024, which we anticipate will enable us to reduce further our net debt and leverage by the end of the year. The board's expectation for full year financial performance is unchanged." Alliance Pharma predicts group profit in line with its 2023 results, of which pretax profit was GBP31.5 million.

----------

Ocean Harvest Technology Group PLC - Reading, England-based researcher, developer and supplier of proprietary blended seaweed products as functional additives for the global animal feed industry - Pretax loss for the six months to June 30 narrows to EUR2.1 million from EUR2.2 million at the same time last year, whilst product revenue falls 48% to EUR831,000 from EUR1.6 million year-on-year after the company's largest customer from 2023 places no orders. Cost of goods sold for the six-month period falls 45% to EUR665,000 from EUR1.2 million. The company says total margins were also negatively impacted by one-off loss-making sales of aged single seaweed inventory. CEO Ashley Head says: "Despite the challenging first half of 2024, the period has been one of positive changes for Ocean Harvest Technology, with the company now being on a solid footing looking ahead to 2025 and beyond. Trial data remains very positive and we are pleased to see the resumption of regular ordering from our largest customer who remains an enthusiastic user of OceanFeed. A loan note facility provides the company with the financial stability it needs to continue to implement the sales initiatives which the board expects to drive revenue growth and improvements in margin going forward. We look forward with great confidence in our product and expect to return to significant growth into 2025."

----------

DG Innovate PLC - Caerphilly, Wales-based electric mobility and energy storage company - Pretax loss for the six months to June 30 is GBP3.0 million compared to GBP1.9 million a year prior, as cost of sales widens to GBP88,771 from GBP24,662 and administrative expenses grow 29% to GBP2.2 million from GBP1.7 million. Turnover rises to GBP116,400 from GBP30,240 at the same time last year.

----------

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer company - Pretax loss for the six months to June 30 widens to GBP1.4 million from GBP457,000 the year before. The company reports no revenue, unchanged year-on-year. Chair Allan Syms says: "Throughout 2024, the group has made significant progress in developing its blood test to help in the early detection of lung cancer through the manufacturing of its core antibodies with BBI Solutions in their ISO 13485-certified facilities; the industrial collaboration with an industry-leading laboratory instrumentation partner; and being selected by the number one cancer centre in Florida to conduct a clinical evaluation of our biomarker for their patients presenting with suspicious lung nodules. Furthermore, the establishment of a partnership with BIO has now moved the business into the commercial phase of bringing our non-invasive, cost effective CIZ1B biomarker lung cancer blood test to market. The partnership with BIO is expected to be completed shortly giving us the potential for a significant guaranteed royalty deal in North America."

----------

By Emily Parsons, Alliance News reporter

Comments and questions to [email protected]

Copyright 2024 Alliance News Ltd. All Rights Reserved.

FTSE 100 Latest
Value8,236.95
Change-83.81